Financials HitGen Inc.

Equities

688222

CNE1000040G3

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
12.6 ^CNY	-1.18%		-6.46%	-15.94%

Apr. 24	HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 23	HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Valuation

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	12,068	9,412	5,401	5,988	5,033	-	-
Enterprise Value (EV) ¹	12,068	9,412	5,401	5,988	5,033	5,033	5,033
P/E ratio	177 x	147 x	225 x	136 x	99.5 x	82.2 x	66.3 x
Yield	-	-	-	0.33%	0.08%	0.08%	-
Capitalization / Revenue	49.5 x	30.3 x	16.4 x	16.1 x	11.5 x	9.98 x	8.22 x
EV / Revenue	49.5 x	30.3 x	16.4 x	16.1 x	11.5 x	9.98 x	8.22 x
EV / EBITDA	142 x	102 x	92 x	76.9 x	74.4 x	65.1 x	36.7 x
EV / FCF	-149 x	-97.7 x	-157 x	83.3 x	219 x	120 x	88.3 x
FCF Yield	-0.67%	-1.02%	-0.64%	1.2%	0.46%	0.83%	1.13%
Price to Book	9.44 x	7.15 x	4.15 x	4.42 x	3.6 x	3.46 x	3.26 x
Nbr of stocks (in thousands)	400,680	400,680	400,680	399,441	399,441	-	-
Reference price ²	30.12	23.49	13.48	14.99	12.60	12.60	12.60
Announcement Date	2/26/21	2/25/22	2/27/23	2/23/24	-	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	243.6	311.1	329.6	371.7	436	504.5	612.5
EBITDA ¹	85.05	92.59	58.69	77.88	67.67	77.33	137
EBIT ¹	59.57	45.76	12.12	35.14	41	49.67	80
Operating Margin	24.46%	14.71%	3.68%	9.46%	9.4%	9.84%	13.06%
Earnings before Tax (EBT) ¹	63.36	55.83	12.44	38.83	42.67	51.33	80
Net income ¹	64.02	63.38	25.27	43.94	50.7	61.08	76
Net margin	26.28%	20.38%	7.66%	11.82%	11.63%	12.11%	12.41%
EPS ²	0.1700	0.1600	0.0600	0.1100	0.1267	0.1533	0.1900
Free Cash Flow ¹	-81.13	-96.33	-34.46	71.91	23	42	57
FCF margin	-33.31%	-30.97%	-10.45%	19.35%	5.28%	8.32%	9.31%
FCF Conversion (EBITDA)	-	-	-	92.33%	33.99%	54.31%	41.61%
FCF Conversion (Net income)	-	-	-	163.63%	45.37%	68.76%	75%
Dividend per Share ²	-	-	-	0.0500	0.0100	0.0100	-
Announcement Date	2/26/21	2/25/22	2/27/23	2/23/24	-	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period:

Estimates

Balance Sheet Analysis

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Free Cash Flow ¹	-81.1	-96.3	-34.5	71.9	23	42	57
ROE (net income / shareholders' equity)	6.26%	4.89%	1.91%	3.3%	3.59%	4.2%	4.89%
ROA (Net income/ Total Assets)	5.61%	3.78%	1.49%	2.58%	2.91%	3.35%	3.9%
Assets ¹	1,142	1,676	1,691	1,700	1,745	1,823	1,949
Book Value Per Share ²	3.190	3.280	3.250	3.390	3.500	3.650	3.870
Cash Flow per Share ²	0	0.1100	0.1300	0.3100	0.1600	0.1800	0.2900
Capex ¹	82.7	140	87.2	53.3	35	32	35
Capex / Sales	33.96%	44.95%	26.45%	14.34%	8.03%	6.34%	5.71%
Announcement Date	2/26/21	2/25/22	2/27/23	2/23/24	-	-	-

¹CNY in Million²CNY

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for HitGen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.6 CNY

Average target price

16 CNY

Spread / Average Target

+26.98%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HITGEN INC.	-15.94%	704M
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	115B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.31B
ARGENX SE	-3.99%	21.6B
BEIGENE, LTD.	-7.19%	18.23B
WUXI APPTEC CO., LTD.	-39.93%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.26B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.37B
LEGEND BIOTECH CORPORATION	-28.60%	8.28B

Bio Therapeutic Drugs